On 23 June, EFPIA has published a comprehensive study on the social and economic value of pharmaceutical innovation. Data shows that between 2014 and 2024 Europe’s investment of €11.67 billion in new medicines returned more than five times the amount in social, economic and hospital cost savings – equating to €66billion in total, including over €9billion in direct hospital savings.
The study examines impact on mortality and hospital utilisation and quantifies the economic returns based on three major disease areas in 29 European countries between 2014 to 2022.
